March 7, 2019
Boston-based Akili Interactive Labs, maker of video game-like treatments for children with ADHD and autism spectrum disorder, has found a partner to help promote its digital therapeutic products in eastern Asia.
Thanks to a new strategic partnership announced this morning, Osaka, Japan-based pharmaceutical company Shionogi will take over the commercialization, marketing, clinical development and...
Left to right: Dr. Daniel Kraft, Fitbit's Any McDonough, Verily's Dr. Jess Mega and Akili's Eddie Martucci chat on stage at CES 2019’s Digital Health Summit
January 9, 2019
Digital therapeutics are a nascent corner of the healthcare technology industry. With few precedents available outside of novel drugs or medical devices, it would make sense that Pear Therapeutics, Proteus and other digital therapeutics companies furthest along the regulatory pipeline align themselves with industry partners well versed in selling and supporting a medical product.
As such, it came...
January 3, 2019
A small feasibility study conducted by the Children’s Hospital of Philadelphia suggests that Project: Evo, the digital medicine developed by Akili Interactive Labs that is delivered via a video game, continually engaged children with autism spectrum disorder (ASD) and reduced their ADHD symptoms, although more objective measures of cognitive control were mixed.
Nineteen children aged...
November 26, 2018
Yadin Shemmer has been named the new CEO of Mango Health, the maker of a digital medication management platform. Shemmer, who was previously the company’s president, will take over the job from founder Jason Oberfest, who will continue to serve as a special advisor to the company.
“I am thrilled to have Yadin take the helm at Mango Health to spearhead the continued growth of the company,”...
September 12, 2018
Digital therapeutics maker Akili Interactive Labs today announced a deal with the University of California’s governing board concerning exclusive licensing of a new technology that will combine the company’s focus on neural systems with physical activity.
Developed at the Neuroscape Lab at UCSF, the tech follows in the footsteps of Akili’s other efforts in that it is primarily delivered through a...
August 9, 2018
Boston-based digital therapeutics company Akili Interactive Labs announced this morning that it has added an extra $13 million to its previously announced Series C financing. Together, this brings the company’s 2018 funding to $68 million, and its total backing to just over $140 million.
The additional investment from CLSA, Omidyar Technology Ventures, Digital Garage Group, and Fearless Ventures...
May 9, 2018
This morning, Boston-based Akili Interactive Labs announced the closure of a $55 million Series C funding round. The investment was led by Temasek, with participation from Baillie Gifford, Amgen Ventures, M Ventures, JAZZ Venture Partners, Canepa Advanced Healthcare Fund, and Brooklands Capital Strategies.
According to the company, this new funding will be used to support development, regulatory...
March 2, 2018
From syringes to workflow management systems, healthcare is no stranger to adopting new technologies into standard care. As digital and connected technologies continue to stake their claim in the industry, the last few years have seen the rise of a new type of health technology product — one that promises measurable health outcomes validated by traditional clinical trials.
“You had a little...
January 11, 2018
For as much promise as technology shows when it comes to healing the body, equally impressive is its potential for the human mind. New therapeutics and devices have shown evidence of repairing damaged nerve passageways, overcoming cognitive disorders, and simply fine-tuning the healthy brain, so it’s no surprise that innovators are rushing to bring these technologies into the mainstream.
December 4, 2017
Boston-based Akili Interactive Labs has announced positive results from the largest clinical trial of its video game-based pediatric ADHD treatment yet. In light of these data, the company announced that it now plans to file AKL-T01, also known as Project: Evo ADHD Treatment, for FDA clearance as a novel treatment for children and adolescents with ADHD
“This is, any way you slice it, our largest...